地舒单抗停药后骨丢失可被阿仑膦酸和唑来膦酸预防而非利塞膦酸:一项回顾性研究
该回顾性研究纳入121例停用地舒单抗(Dmab)的患者,比较停药后未治疗(NT)、利塞膦酸(RIS)、阿仑膦酸(ALN)或唑来膦酸(ZOL)对骨密度(腰椎、股骨颈、全髋)的影响。停药1年后,ALN和ZOL组腰椎骨密度下降小于NT组,而RIS组与NT组无显著差异;7例椎体骨折中5例发生在NT组停药后。
要点
- 停用地舒单抗后,阿仑膦酸或唑来膦酸治疗可减轻腰椎骨密度丢失,利塞膦酸则未见此效果。
- 腰椎骨密度变化:NT组 -0.041 g/cm²,ALN组 -0.005 g/cm²(与NT组差异 p=0.015),ZOL组 -0.009 g/cm²(与NT组差异 p=0.037),RIS组 -0.035 g/cm²(与NT组无显著差异)。
- 全髋仅NT与ZOL组间差异显著(p=0.034),股骨颈各组间无差异;7例椎体骨折中5例发生在NT组停药后。
核心结论
- 停用地舒单抗后,序贯阿仑膦酸或唑来膦酸治疗可减轻骨密度丢失,而未治疗和利塞膦酸则不能。
研究设计与样本
- 回顾性研究纳入121例停用地舒单抗的患者(年龄71.2 ± 8.1岁,平均使用5.4剂),其中33例未治疗,88例接受双膦酸盐治疗(22例利塞膦酸、34例阿仑膦酸、32例唑来膦酸)。
- 比较停药1年后腰椎、股骨颈和全髋的骨密度变化,并比较骨丢失危险因素及椎体骨折发生率。
主要发现
- 腰椎骨密度平均变化(g/cm²,95%CI):NT组 -0.041(-0.062至-0.021);RIS组 -0.035(-0.052至-0.017);ALN组 -0.005(-0.020至0.009);ZOL组 -0.009(-0.025至0.008)。
- 腰椎骨密度变化NT与ALN组间差异有统计学意义(p=0.015),NT与ZOL组间差异有统计学意义(p=0.037),NT与RIS组间无显著差异。
- 全髋仅NT与ZOL组间差异有统计学意义(p=0.034),股骨颈各组间无差异。
- 地舒单抗治疗期间的骨密度增加与停药后的骨密度丢失相关。
- 亚组中,地舒单抗治疗超过5剂后停药并序贯ALN(n=22)或ZOL(n=11)者骨密度无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: A retrospective study of 121 patients who stopped denosumab (Dmab) then received no treatment (NT), risedronate (RIS), alendronate (ALN), or zoledronic acid (ZOL). Bone density (spine and hip) during and after Dmab discontinuation was measured. Treatment with ALN or ZOL, not NT and RIS, mitigated BMD loss after Dmab discontinuation. INTRODUCTION: Denosumab (Dmab) discontinuation is associated with bone loss and multiple vertebral fractures. The purpose was to compare bone mineral density (BMD) change in patients following Dmab discontinuation with no subsequent treatment (NT) and three bisphosphonate (BP) treatments: risedronate (RIS), alendronate (ALN), and zoledronic acid (ZOL). METHODS: In a review of 121 patients aged 71.2 ± 8.1 years, discontinuing Dmab (mean 5.4 doses), 33 received NT and 88 received BP (22 RIS; 34 ALN; 32 ZOL). BMD change after 1 year was compared between groups at the lumbar spine (LS), femoral neck (FN), and total hip (TH). Risk factors for bone loss after Dmab discontinuation were compared between groups and incidence of vertebral fractures was determined. RESULTS: Following Dmab discontinuation, LS mean change (g/cm2; 95% CI) was for NT: - 0.041 (- 0.062 to - 0.021); RIS: - 0.035 (- 0.052 to - 0.017); ALN: - 0.005 (- 0.020 to 0.009); and ZOL: - 0.009 (- 0.025 to 0.008). Differences in LS were found between NT and ALN (p = 0.015), and NT and ZOL (p=0.037), but not between NT and RIS. The only significant difference in TH was found between NT and ZOL (p 0.034) with no group differences in FN. BMD gains during Dmab treatment were associated with BMD loss after Dmab discontinuation. In a subset, discontinuation after Dmab treatment (> 5 doses) followed by ALN (n = 22) and ZOL (n = 11) showed no difference in BMD. Five of 7 vertebral fractures occurred after Dmab discontinuation in NT. CONCLUSION: Subsequent treatment with ALN or ZOL but not NT and RIS mitigates BMD loss after Dmab discontinuation.
引用
- Tutaworn T, Nieves JW, Wang Z, et al. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporos Int. 2023. PMID: 36602607. doi:10.1007/s00198-022-06648-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。